(Q41103757)

26 September 2017

title

Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies (English)

1 reference

26 September 2017

Chatelut M

1

1 reference

26 September 2017

Harzer K

2

1 reference

26 September 2017

Christomanou H

3

1 reference

26 September 2017

Feunteun J

4

1 reference

26 September 2017

Pieraggi MT

5

1 reference

26 September 2017

Paton BC

6

1 reference

26 September 2017

Kishimoto Y

7

1 reference

26 September 2017

O'Brien JS

8

1 reference

26 September 2017

Basile JP

9

1 reference

26 September 2017

Thiers JC

10

1 reference

26 September 2017

Salvayre R

11

1 reference

26 September 2017

Levade T

12

1 reference

26 September 2017

publication date

1 June 1997

1 reference

26 September 2017

1 reference

26 September 2017

volume

262

1 reference

26 September 2017

issue

1-2

1 reference

26 September 2017

page(s)

61-76

1 reference

Activator proteins and topology of lysosomal sphingolipid catabolism.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Saposin D: a sphingomyelinase activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Stimulation of acid ceramidase activity by saposin D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

The serial cultivation of human diploid cell strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

METHODS FOR METHANOLYSIS OF SPHINGOLIPIDS AND DIRECT DETERMINATION OF LONG-CHAIN BASES BY GAS CHROMATOGRAPHY

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Transfer of immortality by transfection of genomic DNA from SV40 established cell lines into rat embryo fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Measurement of protein using bicinchoninic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Ouchterlony double immunodiffusion method demonstrates absence of ferritin immunoreactivity in visceral organs from nine patients with Niemann-Pick disease type C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

A simple method for screening for Farber disease on cultured skin fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Effect of saposins on acid sphingomyelinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

A protein activator of galactosylceramide beta-galactosidase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Establishment of human fibroblast cell lines with lysosomal enzyme deficiency by transformation with origin-minus SV40 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

In vitro establishment of human fibroblasts of lysosomal diseases, GM1-gangliosidosis and Sandhoff disease, by transformation with origin-minus SV40 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Correction of mucolipidosis III in vitro by gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Type C Niemann-Pick disease fibroblasts and their transformed cell lines are hypersensitive to HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Topology of glycosphingolipid degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

Identification of the neurotrophic factor sequence of prosaposin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2897%2906527-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-8981(97)06527-3

1 reference

26 September 2017

1 reference